Search | Clinical Trials Finder

Conditions: Bacteriuria, Spinal Cord Injuries, Asymptomatic Bacteriuria, Escherichia Coli
Interventions: Phage Therapy, Placebo; Drug · Other
Lead sponsor: Barbara Trautner; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: St Louis, Missouri • Houston, Texas

Conditions: HIV Infections
Interventions: DNA Vaccine, DNA Vaccine placebo, rAd35, rAd35 placebo, rAd5, rAd5 placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more

Conditions: Spinal Muscular Atrophy
Interventions: Valproic Acid and Levocarnitine, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 2 Years to 17 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 5
States / cities: Baltimore, Maryland • Detroit, Michigan • Columbus, Ohio + 2 more

Conditions: Bipolar I Disorder
Interventions: olanzapine, placebo, divalproex; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Pre-eclampsia
Interventions: Anti-digoxin antibody (FAB fragment), sodium chloride; Drug · Other
Lead sponsor: BTG International Inc.; Other
Eligibility: Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 8
States / cities: Mobile, Alabama • Phoenix, Arizona • Orlando, Florida + 5 more

Conditions: Allergic Rhinitis, Asthma
Interventions: Cetirizine Hydrochloride 1 MG/ML, Placebo - Concentrate; Drug
Lead sponsor: New York City Health and Hospitals Corporation; Other
Eligibility: 6 Years to 20 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Carcinoma, Squamous Cell of Head and Neck
Interventions: VTX-2337, Carboplatin, Cisplatin, 5-fluorouracil, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 53
States / cities: Little Rock, Arkansas • Beverly Hills, California • Escondido, California + 47 more

Conditions: HIV Prevention
Interventions: PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant, GLA-SE adjuvant, Placebo for DNA Vaccines, Protein Vaccines and Adjuvants; Biological
Lead sponsor: Worcester HIV Vaccine; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Influenza
Interventions: CAIV-T 10^7, CAIVT 10^5, Placebo, TIV; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 6 Months to 36 Months
Enrollment: 173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 2
States / cities: New Port Richey, Florida • Pittsburgh, Pennsylvania

Conditions: Amyotrophic Lateral Sclerosis
Interventions: GM604, Placebo comparator; Drug
Lead sponsor: Genervon Biopharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Healthy Adult Normals
Interventions: BMS-933043, Placebo matching with BMS-933043, Antacid Buffer Predose Solution; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Breast Cancer
Interventions: Veliparib Placebo, Veliparib, Carboplatin, Paclitaxel; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 56
States / cities: Gilbert, Arizona • Little Rock, Arkansas • Duarte, California + 48 more

Conditions: Pharmacokinetics, Safety, Tolerability
Interventions: 5-methoxy-N,N-dimethyltryptamine succinate salt, Placebo; Drug
Lead sponsor: Usona Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Idiopathic Inflammatory Myositis (IIM), DERMATOMYOSITIS OR POLYMYOSITIS
Interventions: ULSC (1.5 x 10^8 cells/dose), Placebo (no cells); Biological
Lead sponsor: Restem, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Gainesville, Florida • Miami, Florida

Conditions: COVID-19 Infection
Interventions: Clazakizumab, Placebo; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Systemic Lupus Erythematosus (SLE)
Interventions: Acthar, Placebo, Steroid Drug; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 22
States / cities: Jonesboro, Arkansas • La Jolla, California • La Palma, California + 17 more

Conditions: Suicide
Interventions: Study Juice, Placebo Juice; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 90 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Carcinoma, Non-Small Cell Lung
Interventions: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel, Carboplatin plus Paclitaxel; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 926 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 80
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 69 more

Conditions: Acute Respiratory Distress Syndrome, Critical Illness, Respiratory Failure, Sepsis
Interventions: Intravenous Acetaminophen (room temperature), Intravenous Vitamin C (refrigerated), 5% Dextrose (room temperature), 5% Dextrose refrigerated; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 41
States / cities: Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more

Conditions: HIV Infections
Interventions: PENNVAX®-GP HIV-1 DNA vaccine, Interleukin-12 (IL-12) DNA adjuvant, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Decatur, Georgia • Rochester, New York • Nashville, Tennessee + 1 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF), Placebo (for ATG), Placebo (for GCSF); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 45 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 13
States / cities: San Francisco, California • Stanford, California • Aurora, Colorado + 10 more

Conditions: Submental Fat
Interventions: 10XB-101 Solution for Injection, 10XB-101 Vehicle Solution for Injection; Drug
Lead sponsor: 10xBio, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Encino, California • San Diego, California • Rolling Meadows, Illinois

Conditions: Shigella Infection
Interventions: Placebo, WRSs2, WRSs3; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Post Traumatic Stress Disorder
Interventions: Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm, Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer., Matching IV Placebo, Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm; Behavioral · Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria

Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector

Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy

A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients

Efficacy Study of Digibind for Treatment of Severe Preeclampsia

The Effect of Cetirizine on Bronchoconstriction

Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children

GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)

Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)

Clazakizumab vs. Placebo - COVID-19 Infection

Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease

The Better Resiliency Among Veterans With Omega-3's (BRAVO) Study

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery

Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults

ATG-GCSF in New Onset Type 1 Diabetes

A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat

Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3

Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.